Supplemental Information

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Authors: Jagoda K. Jasielec, Tadeusz Kubicki, Noopur Raje, Ravi Vij, Donna Reece, Jesus Berdeja, Benjamin A. Derman, Cara A. Rosenbaum, Paul Richardson, Sandeep Gurbuxani, Sarah Major, Brittany Wolfe, Andrew T. Stefka, Leonor Stephens, Kathryn M. Tinari, Tyler Hycner, Alexandra E. Rojek, Dominik Dytfeld, Kent A. Griffith, Todd M. Zimmerman, Andrzej J. Jakubowiak

Study Design and Participants

Inclusion Criteria:

- Transplant-eligible patients aged 18 years or older with NDMM requiring systemic chemotherapy per International Myeloma Working Group (IMWG) uniform criteria were eligible.[21]
- Additional inclusion criteria included: measurable disease per IMWG (serum M-protein ≥ 0·5 g/dL and/or urine M-protein ≥200 mg/24 hours, based on serum protein electrophoresis or quantitative immunoglobulin levels), Eastern Cooperative Oncology Group (ECOG) performance status 0-2, life expectancy of more than 3 months, adequate hepatic function (bilirubin <1·5 times the upper limit of normal [ULN] and aspartate aminotransferase and alanine aminotransferase <2·5 times ULN), absolute neutrophil count ≥1·0 x10^9/L, hemoglobin ≥8g/dL, platelet count ≥75 x 10^9/L, and creatinine clearance of ≥50 mL/minute.

Exclusion Criteria

- Exclusion criteria included grade 3/4 neuropathy or grade 2 neuropathy with pain; non-hematologic malignancies in the past 3 years; POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes); Waldenström's macroglobulinemia; IgM syndrome; significant cardiovascular disease or other comorbidities, including myocardial infarction within 6 months prior to enrolment, New York Heart Association Class III or IV heart failure, or uncontrolled hypertension.

Dose reduction levels

- 27, 20, 15, or 11 mg/m^2 for carfilzomib
- 20, 15, 10, and 5 mg for lenalidomide
- 30, 20, 15, and 10 mg for dexamethasone